Optimising Product Portfolio, Focusing On Key Brands: GSK Pharma
GlaxoSmithKline Pharmaceuticals is optimising its product portfolio with focus on key brands to accelerate growth in India, a senior company official said.
The company is also looking to launch some new products in the country over the next 15 months as it adopts a more structured approach to engage trade channel partners, with a dedicated team to engage stockists and retailers across India.
The business has embarked on it new strategy this year, as we put in place an optimal commercial structure and worked at building capability.A Vaidheesh, MD (India), GSK Pharmaceuticals
“Our new commercial model is in place with increased focus on our priority brands, and expansion in our field force to drive focus, including a new trade channel strategy,” he added.
Vaidheesh said GSK India has over 55 major brands in its portfolio and the company has chosen to focus on dermatology, anti-infectives, pain, hormones, respiratory, gastrointestinal, nutrition/vitamins and vaccines segments.
In the past 12 months, the company has launched two new products -- Infanrix Hexa vaccine (6-in-1 combination DTaP vaccine) and Nucala (mepolizumab) in the respiratory segment.
The new strategy has started yielding results, he said, adding that GSK Pharma's financial performance for Q3 highlighted the outcomes of this execution.
There was headline double-digit sales growth both for the quarter and year to date, underpinned by a strong volume delivery, Vaidheesh said.
On new launches, he said, “Some of the products that we plan to launch in the next 12-15 months are Menveo (meningococcal vaccine), Fluarix Tetra (infuenza vaccine) and Infanrix IPV (DTaP vaccine plus inactivated Polio).”
-
We May Need Another Tukaram Mundhe To Fight Air Pollution | The Reason Why
Developers may install basic measures such as sprinklers and green nets, resume work, and continue violating rules when this equipment stops working.
-
Extracting Value From Battery Scrap Could Be Challenging For India | The Reason Why
A discarded lithium-ion battery still contains valuable materials such as lithium, nickel and cobalt. These can be recovered and reused. When such batteries are crushed and shredded, they produce a dark powder called black mass.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.